Pharmaceuticals, 2023 Combining antiviral drugs with different mechanisms of action can help prevent the development of resistance by attacking the infectious agent through multiple pathways.
Liliana Betancur-Galvis +4 more
doaj +1 more source
The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]
, 2019 The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Alexescu, Teodora G +12 more
core +3 more sources
Broad-Spectrum Antivirals Derived from Natural Products
Viruses, 2023 Scientific advances have led to the development and production of numerous vaccines and antiviral drugs, but viruses, including re-emerging and emerging viruses, such as SARS-CoV-2, remain a major threat to human health.
Wen-Jun Tian, Xiao-Jia Wang
doaj +1 more source
Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. [PDF]
, 2018 Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV cure has been linked to improved patient outcomes. In the era of direct-acting antivirals (DAAs), HCV cure has become the goal, as defined by sustained virological response ...
Benhammou, Jihane N +9 more
core +1 more source
New horizons in hepatitis C antiviral therapy with direct-acting antivirals [PDF]
Hepatology, 2013 Abstract Most direct-acting antivirals (DAAs) that are being developed as therapy against hepatitis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide analogues as well as a number of allosteric sites ...
Aghemo, Alessio, De Francesco, Raffaele
openaire +2 more sources
Case Reports in Gastroenterology, 2015 Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasionally
Tatsuo Kanda +11 more
doaj +1 more source
Hepatitis C at presentation in a newly diagnosed infant with B Acute Lymphoblastic Leukemia
Pediatric Hematology Oncology Journal, 2018 We report the unique case of a nine-month old patient diagnosed with B- Cell Acute Lymphoblastic Leukemia also positive for Hepatitis C virus, genotype 3 and a high viral load.
Qurratulain Shahood Ahmed +3 more
doaj +1 more source
Научно-практическая ревматология, 2023 Objective – to evaluate the long-term outcomes of HCV eradication with direct-acting antivirals (DAAs) in patients with hepatitis C-associated cryoglobulinemic vasculitis (HCV-CV)Materials and methods.
S. V. Gavrisheva +11 more
doaj +1 more source
Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals [PDF]
, 2017 In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because ...
Caputo, Mariela +4 more
core +1 more source
Self-reported experience in patients treated with Hepatitis C direct acting antivirals [PDF]
Farmacia Hospitalaria, 2016 Background and objective: To learn about and analyze the self-reported treatment experience of HCV patients who started treatment with direct acting antivirals agents (DAA), at a real-time, proactive and integrated into the pharmaceutical care healthcare
Irene Cañamares Orbis +5 more
doaj +1 more source